^
    Back
    Association details:
    Biomarker:PIK3CA R88Q + PD-L1 expression
    Cancer:Ovarian Cancer
    Drug:everolimus (mTOR inhibitor) +
    Loqtorzi (toripalimab-tpzi) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Dovepress
    Title:

    Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review

    Published date:
    12/09/2021
    Excerpt:
    In this study, a PIK3CA p.R88Q mutation and PD-L1 expression with a tumor proportion score of 10% was explored in a patient...she was administered a novel combinatorial therapy comprising mTOR inhibitor everolimus...the anti-PD-1 antibody toripalimab. Treatment with this combinatorial therapy showed good prognosis, with more than eight months of disease control...The findings of this study provide a novel and effective strategy for OCCC patients.
    DOI:
    https://doi.org/10.2147/OTT.S333029